Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Safety and Efficacy of In Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand Automated Process and Delivered via Helix Biotherapeutic Delivery System for the Treatment of Patients Soon After a Heart Attack

Next Previous
Trial Profile

A Study to Evaluate the Safety and Efficacy of In Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand Automated Process and Delivered via Helix Biotherapeutic Delivery System for the Treatment of Patients Soon After a Heart Attack

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 10 Nov 2018 New trial record
  • 30 Oct 2018 According to a BioCardia media release, if the study results in regulatory approval of the product, CellProThera will have exclusive commercial rights in Singapore to the Helix Biotherapeutic Delivery System for the delivery of culture expanded CD34+ cells to treat patients who have suffered a recent heart attack. BioCardia will receive double-digit royalty payments on future sales of the combination product.
  • 30 Oct 2018 According to a BioCardia media release, CellProThera and BioCardia have announced an agreement to expand their current collaboration to the SIngXpand Clinical Trial in Singapore.Under the terms of the agreement, CellProThera will fund completion of all regulatory and clinical activities undertaken by both firms for the clinical investigation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top